{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 20,
  "pageCount": 45,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "BOND-003 clinical trial safety data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/20",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.042
      },
      "kind": "list",
      "text": "Nearly all AEs were transient Grade 1-2 local urinary tract symptoms; No Grade ≥ 3 treatment-related AEs reported; Two patients (1.8%) had SAEs (Grade 2); No treatment discontinuations due to AEs; No deaths were reported",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f1e99f6-edf9-4ee0-aa88-70b4772858b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Safety data cutoff as of September 8, 2023. Treatment-related SAEs were noninfective cystitis (Grade 2) and clot retention (Grade 2).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "653e6d12-395e-4e8e-9d42-db004aaf0e4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "subtitle",
      "text": "Top Adverse Events Considered Related to Cretostimogene Administration For All Patients (n=112) By Grade",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6564db37-d933-4cff-9dce-9a0f94d91d6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.046,
        "y": 0.039
      },
      "kind": "table",
      "text": "Patients with TRAEs; Any Grade (%); Grade ≥ 3 (%); Bladder Spasm; Pollakiuria; Dysuria; Micturition Urgency; Hematuria",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a706b463-83bf-40d3-b711-e01c9c6cfe3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Cretostimogene Has Been Generally Well-Tolerated With No Grade 3 Or Higher Treatment-Related AEs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cc3b81d-8b9f-4a08-bee1-5754b72ef184",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}